Merck KGaA (MKKG.Y) Stock Overview
Operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for MKKG.Y from our risk checks.
MKKG.Y Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Merck KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €32.84 |
| 52 Week High | €34.19 |
| 52 Week Low | €23.73 |
| Beta | 0.83 |
| 1 Month Change | 4.79% |
| 3 Month Change | 30.37% |
| 1 Year Change | 28.23% |
| 3 Year Change | 2.53% |
| 5 Year Change | -18.55% |
| Change since IPO | 172.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| MKKG.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.6% | 1.4% | 1.6% |
| 1Y | 28.2% | 48.6% | 18.6% |
Return vs Industry: MKKG.Y underperformed the US Pharmaceuticals industry which returned 48.6% over the past year.
Return vs Market: MKKG.Y exceeded the US Market which returned 18.6% over the past year.
Price Volatility
| MKKG.Y volatility | |
|---|---|
| MKKG.Y Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MKKG.Y has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MKKG.Y's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1668 | 59,077 | Kai Beckmann | www.emdgroup.com |
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization.
Merck KGaA Fundamentals Summary
| MKKG.Y fundamental statistics | |
|---|---|
| Market cap | US$71.03b |
| Earnings (TTM) | US$2.89b |
| Revenue (TTM) | US$23.94b |
Is MKKG.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MKKG.Y income statement (TTM) | |
|---|---|
| Revenue | €20.96b |
| Cost of Revenue | €8.61b |
| Gross Profit | €12.35b |
| Other Expenses | €9.82b |
| Earnings | €2.53b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 06, 2026
| Earnings per share (EPS) | 5.82 |
| Gross Margin | 58.93% |
| Net Profit Margin | 12.08% |
| Debt/Equity Ratio | 40.4% |
How did MKKG.Y perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 22:46 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Merck KGaA is covered by 42 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Odile Rundquist | Baader Helvea Equity Research |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Charles Pitman | Barclays |